Predictive biomarkers for anti-TNF alpha therapy in IBD patients

Table 2 Putative biomarkers for evaluating anti-TNF therapeutic efficacy in UC patients

^aA reduced mucosal transcript levels of IL-7R also observed in responders to immunosuppressive/corticosteroids, anti-TNF, or anti-a4b7 therapies in both severe UC patients. TNF-α tumour necrosis factor-α, IFN-γ interferon-γ, IL-17A interleukin-17A, miRNAs MicroRNAs, OSM Oncostatin M, IL-7R interleukin-7 receptor, ↓ increase in expression, -: not known. A, adenine, C cytosine, chr chromosome, G guanine, MAF minor allele frequency, NR no response, OR odds ratio, R response, T thymine, TNF tumour necrosis factor, CI confidence interval, IBD inflammatory bowel disease, TREM1 Triggering receptor expressed on myeloid cells 1. HP- Haptoglobin, CD177-NB1 glycoprotein, GPR84-G-protein coupled receptor 84, CST7-Cystatin F, S100A12- S100 calcium-binding protein A12, ARG1-arginase 1, ANXA3-Annexin A3, ANKRD22- ankyrin repeat domain 22

ISSN: 1479-5876